Management of Hyperparathyroidism

Surgical Management of Primary Hyperparathyroidism

Surgical excision of abnormal parathyroid tissue is the only definitive cure for primary hyperparathyroidism, with preoperative localization with ultrasound and/or 99mTc-sestamibi scintigraphy with SPECT/CT recommended, and surgical options including minimally invasive parathyroidectomy (MIP) or bilateral neck exploration (BNE) 1
Indications for parathyroidectomy include osteoporosis, as recommended by the Kidney International guideline society 2

Control serum phosphorus through dietary phosphorus restriction and phosphate binders in patients with CKD-related secondary hyperparathyroidism, as recommended by the Praxis Medical Insights guideline society 3
Decisions about phosphate-lowering treatment should be based on progressively or persistently elevated serum phosphate, according to the Kidney International guideline society 2
Restrict the dose of calcium-based phosphate binders in adult patients with CKD G3a-G5D, as recommended by the Kidney International guideline society 2

For patients with CKD stages G3a-G5 not on dialysis with progressively rising or persistently elevated PTH levels, evaluate for modifiable factors including hyperphosphatemia, hypocalcemia, high phosphate intake, and vitamin D deficiency, as recommended by the Kidney International guideline society 2
In patients with CKD G3a-G5 not on dialysis, calcitriol and vitamin D analogs should not be routinely used, according to the Kidney International guideline society 2
Reserve calcitriol and vitamin D analogs for patients with CKD G4-G5 with severe and progressive hyperparathyroidism, as recommended by the Kidney International guideline society 2

For hemodialysis or peritoneal dialysis patients with intact PTH levels >300 pg/mL, administer active vitamin D sterol (calcitriol, alfacalcidol, paricalcitol, or doxercalciferol) to reduce PTH to 150-300 pg/mL, as recommended by the American Journal of Kidney Diseases guideline society 4
Intermittent intravenous administration of calcitriol is more effective than daily oral calcitriol in lowering serum PTH levels, according to the American Journal of Kidney Diseases guideline society 4

Maintain intact PTH levels in the range of approximately 2-9 times the upper normal limit for the assay in patients with CKD G5D, as recommended by the Kidney International guideline society 2
For patients requiring PTH-lowering therapy, use calcimimetics, calcitriol, vitamin D analogs, or a combination, according to the Kidney International guideline society 2
Monitor serum calcium and phosphorus every 2 weeks for 1 month after initiating vitamin D therapy or increasing the dose, then monthly thereafter, as recommended by the American Journal of Kidney Diseases guideline society 4
Measure PTH monthly for at least 3 months and then every 3 months once target levels are achieved, according to the American Journal of Kidney Diseases guideline society 4

Consider parathyroidectomy for patients with severe hyperparathyroidism (persistent serum levels of intact PTH >800 pg/mL) associated with hypercalcemia and/or hyperphosphatemia refractory to medical therapy, as recommended by the American Journal of Kidney Diseases guideline society 5
Effective surgical options include subtotal parathyroidectomy or total parathyroidectomy with parathyroid tissue autotransplantation, according to the American Journal of Kidney Diseases guideline society 5
Total parathyroidectomy may be superior to total parathyroidectomy with autotransplantation in terms of lower recurrence rates, as recommended by the Praxis Medical Insights guideline society 3

Monitor ionized calcium every 4-6 hours for the first 48-72 hours after surgery, then twice daily until stable, as recommended by the American Journal of Kidney Diseases guideline society 5
If ionized calcium falls below normal (<0.9 mmol/L), initiate calcium gluconate infusion at 1-2 mg elemental calcium per kg body weight per hour, according to the American Journal of Kidney Diseases guideline society 5
When oral intake is possible, administer calcium carbonate 1-2 g three times daily and calcitriol up to 2 μg/day, as recommended by the American Journal of Kidney Diseases guideline society 5
Adjust or discontinue phosphate binders based on serum phosphorus levels, according to the American Journal of Kidney Diseases guideline society 5

For secondary hyperparathyroidism due to vitamin D deficiency, supplement with vitamin D to achieve 25-OH vitamin D levels >20 ng/ml, as recommended by the Praxis Medical Insights guideline society 1

For patients on treatment, monitor serum calcium, phosphorus, and PTH regularly based on CKD stage and presence of abnormalities, as recommended by the Kidney International guideline society 2
For patients with adynamic bone disease (intact PTH <100 pg/mL), allow plasma levels of PTH to rise by decreasing doses of calcium-based phosphate binders and vitamin D or eliminating such therapy, according to the American Journal of Kidney Diseases guideline society 5

In patients undergoing parathyroidectomy, preoperative and postoperative use of active vitamin D derivatives may reduce the incidence of severe hypocalcemia, according to the Kidney International guideline 6
Recent reports highlight the risks of iatrogenic hypocalcemia in situations of rapid bone remineralization after correction of hyperparathyroid bone disease (hungry bone syndrome) following parathyroidectomy, as noted in the Kidney International journal 6
Data from retrospective studies and pilot trials have used prediction models with bone turnover markers to guide postoperative need for calcium supplementation, as reported in the Kidney International journal 6
One observational study suggested that a short-acting bisphosphonate could attenuate hungry bone syndrome after parathyroidectomy, though there is concern this could potentially limit bone remineralization, according to the Kidney International journal 6

In patients with concurrent chronic kidney disease, management differs based on CKD stage and requires balancing hypocalcemia treatment against risks of vascular calcification, as recommended by the Kidney International guideline 7
For CKD Stage 3a patients post-parathyroidectomy, do not initiate active vitamin D therapy (calcitriol) unless PTH becomes severely and progressively elevated, as advised by the Kidney International guideline 7
Reserve calcitriol for CKD G4-G5 patients with severe progressive hyperparathyroidism, according to the Kidney International guideline 7